PMID- 20039930
OWN - NLM
STAT- MEDLINE
DCOM- 20100511
LR  - 20220310
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 40
IP  - 2
DP  - 2010 Feb
TI  - Suppressive effect of COX2 inhibitor on the progression of adipose inflammation 
      in high-fat-induced obese rats.
PG  - 164-71
LID - 10.1111/j.1365-2362.2009.02239.x [doi]
AB  - BACKGROUND: The aim was to examine whether the inhibition of selective 
      cyclooxygenase (COX) 2 activation could suppress the development of inflammatory 
      reaction in visceral and subcutaneous abdominal fats of high-fat-induced obese 
      rats. MATERIALS AND METHODS: The rats were fed separately regular diet (CONT), 
      high-fat diet ad libitum or energy-restrictedly (HFr) for 12 weeks. Rats fed 
      high-fat diet ad libitum were further divided into those co-treated with vehicle 
      (HFa), a selective COX2 inhibitor-celecoxib (HFa-Cel) or nimesulide (HFa-Nim). 
      Oral glucose tolerance test (OGTT) was performed at the end of weeks 4, 8, 12. 
      Another set of rats with similar grouping was divided into those with a 4-, 8- or 
      12-week intervention for tissue sampling. RESULTS: Body and epididymal fat 
      weights were increased similarly in HFa, HFa-Cel and HFa-Nim. Time-dependent 
      increases in plasma insulin, triglyceride, impaired OGTT shown in HFa were 
      significantly reversed in HFa-Cel and HFa-Nim. The obese-linked increases in gene 
      expressions of COX-2, monocyte chemoattractant protein-1 (MCP-1) and tumour 
      necrosis factor-alpha (TNF-alpha) in epididymal and subcutaneous fats (especially 
      in the former) were significantly suppressed in HFa-Cel and HFa-Nim. The protein 
      contents of MCP-1 and TNF-alpha in epididymal fats were changed consistently with 
      their gene expressions. Plasma MCP-1 was increased time-dependently in HFa and 
      suppressed in HFa-Cel and HFa-Nim. The increased CD68 positive cells showed in 
      both epididymal and subcutaneous fats of HFa were significantly attenuated in 
      HFa-Cel and HFa-Nim. CONCLUSIONS: Our findings suggest that COX2 activation is 
      crucially involved in the development of inflammatory response in adipose tissues 
      of high-fat-induced obese rats.
FAU - Hsieh, P-S
AU  - Hsieh PS
AD  - National Defense Medical Center, Taipei, Taiwan. pshsieh@hotmail.com
FAU - Lu, K-C
AU  - Lu KC
FAU - Chiang, C-F
AU  - Chiang CF
FAU - Chen, C-H
AU  - Chen CH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091221
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Blood Glucose)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Fats)
RN  - 0 (Insulin)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - JCX84Q7J1L (Celecoxib)
RN  - V4TKW1454M (nimesulide)
SB  - IM
MH  - Adiposity/drug effects
MH  - Animals
MH  - Antigens, CD
MH  - Antigens, Differentiation, Myelomonocytic
MH  - Blood Glucose/analysis
MH  - Blood Pressure
MH  - Celecoxib
MH  - Chemokine CCL2/analysis
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology
MH  - Disease Models, Animal
MH  - Fats/administration & dosage
MH  - Glucose Tolerance Test
MH  - Immunohistochemistry
MH  - Inflammation/pathology
MH  - Insulin/analysis
MH  - Intra-Abdominal Fat/chemistry/*drug effects/pathology
MH  - Obesity/blood/genetics/*physiopathology
MH  - Polymerase Chain Reaction/methods
MH  - Pyrazoles/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Subcutaneous Fat, Abdominal/chemistry/*drug effects/pathology
MH  - Sulfonamides/*pharmacology
MH  - Triglycerides/blood
MH  - Tumor Necrosis Factor-alpha/analysis
EDAT- 2009/12/31 06:00
MHDA- 2010/05/12 06:00
CRDT- 2009/12/31 06:00
PHST- 2009/12/31 06:00 [entrez]
PHST- 2009/12/31 06:00 [pubmed]
PHST- 2010/05/12 06:00 [medline]
AID - ECI2239 [pii]
AID - 10.1111/j.1365-2362.2009.02239.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2010 Feb;40(2):164-71. doi: 10.1111/j.1365-2362.2009.02239.x. 
      Epub 2009 Dec 21.